Chemistry:Lodenafil
 | |
| Clinical data | |
|---|---|
| Trade names | Helleva |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H32N6O5S |
| Molar mass | 504.61 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Lodenafil (also known as hydroxyhomosildenafil, trade name Helleva) is a drug belonging to a class of drugs called PDE5 inhibitor, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. Like udenafil and avanafil it belongs to a new generation of PDE5 inhibitors.
Lodenafil is formulated as a prodrug in the form of the carbonate ester dimer, lodenafil carbonate, which breaks down in the body to form two molecules of the active drug lodenafil. This formulation has higher oral bioavailability than the parent drug.[1]
It is manufactured by Cristália Produtos Químicos e Farmacêuticos in Brazil and sold there under the brand-name Helleva.[2]
It has undergone Phase III clinical trials,[3][4] but is not yet approved for use in the United States by the U.S. Food and Drug Administration.
See also
References
- ↑ "Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum". European Journal of Pharmacology 591 (1–3): 189–95. September 2008. doi:10.1016/j.ejphar.2008.06.055. PMID 18593576.
- ↑ Cristália Product page. Retrieved on September 16, 2009.
- ↑ "Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial". The Journal of Sexual Medicine 6 (2): 553–7. February 2009. doi:10.1111/j.1743-6109.2008.01079.x. PMID 19040623.
- ↑ "Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial". The Journal of Sexual Medicine 7 (5): 1928–1936. February 2010. doi:10.1111/j.1743-6109.2010.01711.x. PMID 20214718.
{{Navbox
| name = Sexual dysfunction pharmacotherapies | title = Sexual dysfunction pharmacotherapies | state = autocollapse | bodyclass = hlist | listclass = hlist
| group1 = Dopamine agonists | list1 =
- Apomorphine
- Cabergoline
- Lisuride
- Pergolide
- Piribedil
- Pramipexole
- Quinagolide
- Ropinirole
- Rotigotine
- Terguride
| group2 = Melanocortin agonists | list2 =
| group3 = PDE5 inhibitors | list3 =
- Acetildenafil
- Aildenafil
- Avanafil
- Icariin
- Lodenafil
- Mirodenafil
- Nitrosoprodenafil
- Sildenafil
- Sulfoaildenafil
- Tadalafil
- Udenafil
- Vardenafil
| group4 = Sex steroids | list4 =
- Androgens (e.g., [[testosterone, methyltestosterone, other anabolic steroids)
- Estrogens (e.g., [[estradiol, ethinylestradiol, conjugated equine estrogens (Premarin))
- Progestogens (e.g., [[progesterone, progestins)
- Mixed (e.g., tibolone)
| group5 = Others | list5 =
- Afrodor (acecarbromal, quebracho, vitamin E)
- Alkyl nitrites
- Alprostadil
- Amantadine
- Bupropion
- Buspirone
- Cyproheptadine
- Dapoxetine
- Flibanserin
- Mirtazapine
- Moxisylyte
- Oxytocin
- Papaverine
- Phentolamine
- Psychostimulants (e.g., amphetamines, cocaine, methylphenidate)
- Rauwolscine (Rauvolfia)
- Trazodone
- Yohimbine (Yohimbe)
| below =
}}
 |  |
